FEATURED EDITORIAL
The radiotherapy company's novel SADA construct uses self-assembling tetramers to deliver isotopes directly to cancer cells for a highly targeted, less toxic treatment.
- Good Distribution Practice Is Evolving — Here's How
- The 3 Phases of QRM – An Inspector's View
- Lilly's CEO Building On The Trump Agenda
- ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy
- The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials
- A Case For Paying Allogeneic Cell Therapy Product Donors
- Protecting Intellectual Property In The Genomics Revolution
GUEST COLUMNISTS
-
Good Distribution Practice Is Evolving — Here's How
Managing a global supply chain for increasingly complex biologic drugs takes special attention and expertise. Explore the key drivers of a modern logistics management plan.
-
The 3 Phases of QRM – An Inspector's View
Quality resource management has three phases: assessment, control, and review. The experts at GMP Compliance Advisor bring us this breakdown of all of them.
-
ADCs Unleashed: Navigating Development Hurdles In Targeted Cancer Therapy
Despite their potential to revolutionize treatment paradigms, antibody-drug conjugates (ADCs) face challenges that companies must tackle for successful development.
-
The Potential Impact Of U.S. Tariffs On The Biotech Sector: Manufacturing, Funding, And Clinical Trials
Syner-G Biopharma Group's Raymond Forslund, Ph.D., MBA explores how U.S. tariffs might affect biotech manufacturing, funding, and clinical research.
-
A Case For Paying Allogeneic Cell Therapy Product Donors
The debate over whether to pay donors for cell therapy starting materials comes down to four areas of disagreement: altruism, availability, ethics, and safety.
-
Protecting Intellectual Property In The Genomics Revolution
Providing superior IP protection for genomics-related inventions already requires — and will require in the future — a more nuanced strategy combining patents, trade secrets, and copyrights.
-
April 2025 — CDMO Opportunities And Threats Report
Each month, Outsourced Pharma works in conjunction with PharmSource, part of GlobalData, to present its “Contract Manufacturing: Opportunities and Threats (CMOT) Report” to our readers. The report identifies CDMOs that might be impacted by key events affecting their clients, including company acquisitions, product acquisitions and licenses, product approvals, late clinical product terminations, and FDA rejections.
-
Incorporating AI Tools Into Downstream Process Optimization
Data-driven, hybrid modeling complements mechanistic thinking by reducing computational load for faster decision-making when time is a critical consideration.
PHARMA OUTSOURCING WHITE PAPERS
-
Whitepaper: In Vivo Testing Of Nasal Dosage Forms
Explore how innovative nasal drug delivery strategies can unlock faster, patient-friendly therapeutic solutions by combining smart formulation, advanced testing platforms, and rigorous preclinical evaluation.
-
Regulatory Frameworks For mRNA Therapeutics
The RNA therapeutics and vaccines market has grown rapidly, driven by siRNA and mRNA technologies. Explore how these advancements are now being applied to cancer vaccines and innovative therapeutics.
-
Leveraging Efficiency From CLD To Clinical Manufacturing Of mAbs
Discover how our efficient strategies can propel your mAb from discovery to clinical manufacturing in as little as 18 months.
-
Achieving Rapid, High-Titer Expression For Next-Generation Biologics
This advanced cell line development technology overcomes production challenges related to the expression and scalability of complex biologics.
-
Tablet Manufacturing Technologies For Solid Drug Formulation
Compressed tablets are common oral solid dosages that contain the API and various excipients. Learn about the critical steps in selecting manufacturing methods and excipients to achieve the desired therapeutic effects and stability.
-
Establishing Commercial Manufacturing Services For ADCs
Explore how one organization built upon 15+ years of experience and an extensive knowledge base of biologics manufacturing to establish commercial-scale ADC manufacturing capabilities.
PHARMA OUTSOURCING APP NOTES & CASE STUDIES
NEWSLETTER ARCHIVE

REPORTING: TRUMP VS. PHARMA?
REPORTING: U.S. BIOSECURE ACT
CONTENT COLLECTIONS

A great resource to help you find and evaluate the best CDMOs in the world. Included in this CDMO Leadership Awards issue are some insightful articles on development and manufacturing outsourcing.
More Content CollectionsPRODUCTS & SERVICES
ON-DEMAND WEBINARS
- Utilizing A Stepwise Approach For Nitrosamine Risk Mitigation
- Little Patients, Big Challenges: Developing Pediatric Formulations
- The Importance Of Cognitive And Pharmacodynamic Testing During FIH Trials
- PUPSIT Without The Pain: Practical Solutions For Implementation
- CLD To Upstream Optimization: Enhancing Biologics Quality, Productivity